Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TNXP Tonix Pharmaceuticals Holding Co

未开盘 02-09 16:00:00 EST

16.25

-0.09

-0.55%

盘后16.70

+0.45+2.77%

19:52 EST

最高16.59	最低15.85	成交量23.32万
今开16.15	昨收16.34	日振幅4.53%
总市值2.08亿	流通市值1.86亿	总股本1,279万
成交额379.62万	换手率2.03%	流通股本1,147万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TNXP","market":"US","secType":"STK","nameCN":"Tonix Pharmaceuticals Holding Co","latestPrice":16.25,"timestamp":1770670800000,"preClose":16.34,"halted":0,"volume":233246,"hourTrading":{"tag":"盘后","latestPrice":16.7,"preClose":16.25,"latestTime":"19:52 EST","volume":3032,"amount":49913.61,"timestamp":1770684766878,"change":0.45,"changeRate":0.027692,"amplitude":0.056615},"delay":0,"changeRate":-0.005507955936352501,"floatShares":11470800,"shares":12788100,"eps":-16.224855,"marketStatus":"未开盘","change":-0.09,"latestTime":"02-09 16:00:00 EST","open":16.15,"high":16.59,"low":15.85,"amount":3796185.2434219997,"amplitude":0.045288,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-16.224855,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":16.34,"preHourTrading":{"tag":"盘前","latestPrice":16.13,"preClose":16.34,"latestTime":"09:29 EST","volume":1773,"amount":28661.036121,"timestamp":1770647399999,"change":-0.21,"changeRate":-0.012852,"amplitude":0.017748},"postHourTrading":{"tag":"盘后","latestPrice":16.7,"preClose":16.25,"latestTime":"19:52 EST","volume":3032,"amount":49913.61,"timestamp":1770684766878,"change":0.45,"changeRate":0.027692,"amplitude":0.056615},"volumeRatio":0.641616,"impliedVol":1.4481,"impliedVolPercentile":0.8073},"requestUrl":"/m/hq/s/TNXP","defaultTab":"news","newsList":[{"id":"1189073772","title":"Tonix制药：Tonmya在三期RESILIENT研究中较安慰剂显著缓解纤维肌痛疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=1189073772","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189073772?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:09","pubTimestamp":1769774948,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp.（TNXP）旗下药物Tonmya在关键性三期RESILIENT临床试验中取得突破性成果。研究数据显示，与安慰剂组相比，Tonmya治疗组在纤维肌痛患者疼痛症状改善方面表现出统计学意义的显著优势。\n该结果标志着纤维肌痛治疗领域的重要进展，为Tonix Pharmaceuticals后续向监管机构提交新药申请奠定了坚实基础。公司表示将继续推进相关数据分析工作，并积极筹备后续申报流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","TNXP"],"gpt_icon":0},{"id":"1119937454","title":"Tonix制药在2026年非阿片类疼痛治疗峰会上公布Tonmya™三期RESILIENT研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1119937454","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119937454?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:04","pubTimestamp":1769774685,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Co（TNXP）在近日举办的2026年非阿片类疼痛治疗峰会上，正式公布了其创新药物Tonmya™（环苯扎林盐酸盐舌下片）的三期临床试验RESILIENT研究数据。该研究针对纤维肌痛症患者群体，结果显示Tonmya™在改善疼痛症状方面表现出显著疗效与良好安全性。此次数据发布进一步验证了舌下给药技术在非阿片类镇痛领域的应用潜力，为慢性疼痛治疗提供了新思路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0},{"id":"1116595541","title":"Point72资产管理公司申报被动持股Tonix制药9.2%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1116595541","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116595541?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:14","pubTimestamp":1767215655,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，截至12月29日，Point72资产管理公司已持有Tonix制药（Tonix Pharmaceuticals）9.2%的被动股权。这一持股比例表明，Point72对这家生物制药公司展现出了显著的投资兴趣。\n被动持股通常意味着投资机构不寻求对公司施加控制或影响，而是基于投资价值进行财务布局。Tonix制药作为一家专注于开发中枢神经系统疾病和治疗性疫苗的生物技术企业，此次获得知名对冲基金的持股，可能引发市场对其未来发展的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4139","BK4583"],"gpt_icon":0},{"id":"1127857749","title":"Tonix制药宣布2000万美元直接售股后股价上涨5.9%（更正：删除盘前交易相关表述）","url":"https://stock-news.laohu8.com/highlight/detail?id=1127857749","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127857749?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:52","pubTimestamp":1767019945,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp.（纳斯达克：TNXP）在宣布达成2000万美元的直接股票发行协议后，股价显著攀升5.9%。此次交易由机构投资者参与，公司将以每股特定价格直接发行普通股。\n消息公布后，市场反应积极，投资者信心得到提振。该笔资金将用于推进公司临床阶段项目的研发，包括针对中枢神经系统疾病和免疫学疗法的研究。公司管理层表示，此次融资将加强其资产负债表，并为关键管线的进展提供资金支持。\n（注：本报道已更正，移除了此前版本中关于盘前交易的不准确表述。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"1148125980","title":"Tonix制药公布针对莱姆病季节性预防的长效单抗Tnx-4800最新进展 已具备推进2/3期临床试验条件","url":"https://stock-news.laohu8.com/highlight/detail?id=1148125980","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148125980?lang=zh_cn&edition=full","pubTime":"2025-12-29 20:46","pubTimestamp":1767012400,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp.（简称Tonix制药）近日披露了其长效单克隆抗体Tnx-4800的研发计划更新。该抗体药物专为莱姆病的季节性预防而设计，目前已具备进入2/3期临床试验的成熟条件。\nTnx-4800作为一款创新疗法，旨在通过单次注射提供整个莱姆病高发季节的持续保护。此次进展标志着该药物在预防蜱媒传染病领域迈出关键一步。公司表示将基于现有数据与监管机构密切沟通，加快推进临床研究进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","TNXP"],"gpt_icon":0},{"id":"1110103195","title":"Tonix Pharmaceuticals获得罗格斯大学授予的选择性Sigma-1受体拮抗剂Tnx-4900的许可，用于慢性神经性疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=1110103195","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110103195?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:01","pubTimestamp":1765886474,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals获得罗格斯大学授予的选择性Sigma-1受体拮抗剂Tnx-4900的许可，用于慢性神经性疼痛","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"1165886549","title":"Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症","url":"https://stock-news.laohu8.com/highlight/detail?id=1165886549","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165886549?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:02","pubTimestamp":1763985760,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals获得FDA批准开展Tnx-102 SLⅡ期研究以治疗重度抑郁症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"1166751996","title":"Tonix Pharmaceuticals宣布Tonmya™（盐酸环托品舌下片）在美国商业上市，成为首个治疗纤维肌痛的创新药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1166751996","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166751996?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:01","pubTimestamp":1763380901,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布Tonmya™（盐酸环托品舌下片）在美国商业上市，成为首个治疗纤维肌痛的创新药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"1146414586","title":"Tonix Pharmaceuticals与麻省总医院合作推进Tnx-1500抗Cd40l单抗二期临床试验以预防肾移植器官排斥","url":"https://stock-news.laohu8.com/highlight/detail?id=1146414586","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146414586?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:01","pubTimestamp":1762257661,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals与麻省总医院合作，推进其二期临床试验，研究二聚体Fc改造的抗Cd40l单抗Tnx-1500，以预防肾脏移植中的器官排斥反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","TNXP"],"gpt_icon":0},{"id":"1107329917","title":"Tonix Pharmaceuticals宣布首位患者在马萨诸塞州综合医院进行的研究中接受Tonix鼻用助效催产素的第一次给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1107329917","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107329917?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:01","pubTimestamp":1761130884,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布首位患者在由马萨诸塞州综合医院进行的调查者发起的焦点研究中接受Tonix鼻用助效催产素的第一次给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"1148493950","title":"Tonix Pharmaceuticals任命Ganesh Kamath为市场准入负责人，进一步充实商业领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1148493950","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148493950?lang=zh_cn&edition=full","pubTime":"2025-09-30 20:33","pubTimestamp":1759235588,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals任命Ganesh Kamath为市场准入负责人，进一步充实商业领导团队","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"1193478502","title":"Tonix Pharmaceuticals计划在2026年启动Tnx-2900（鼻内增强催产素）治疗普拉德-威利综合征的2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1193478502","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193478502?lang=zh_cn&edition=full","pubTime":"2025-09-29 19:04","pubTimestamp":1759143856,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals计划在2026年启动Tnx-2900（鼻内增强催产素）治疗普拉德-威利综合征的2期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","TNXP"],"gpt_icon":0},{"id":"1174825720","title":"Tonix Pharmaceuticals宣布TNX-102 SL治疗重度抑郁症的FDA预IND会议获得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174825720","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174825720?lang=zh_cn&edition=full","pubTime":"2025-09-18 20:00","pubTimestamp":1758196828,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布TNX-102 SL治疗重度抑郁症的FDA预IND会议获得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4139","BK4583"],"gpt_icon":0},{"id":"1196311138","title":"Tonix Pharmaceuticals宣布授权引入已准备进入2/3期临床试验的单克隆抗体，用于季节性预防莱姆病（Tnx-4800）","url":"https://stock-news.laohu8.com/highlight/detail?id=1196311138","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196311138?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:01","pubTimestamp":1758106891,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals宣布授权引入已准备进入2/3期临床试验的单克隆抗体，用于季节性预防莱姆病（Tnx-4800）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","TNXP"],"gpt_icon":0},{"id":"1175517857","title":"盘前异动 | TNXP飙升11%，迅雷涨超15%！BMNR等加密股走低","url":"https://stock-news.laohu8.com/highlight/detail?id=1175517857","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175517857?lang=zh_cn&edition=full","pubTime":"2025-08-18 16:14","pubTimestamp":1755504855,"startTime":"0","endTime":"0","summary":"8月18日，美股三大股指期货下跌，截止发稿，道指期货跌0.29%，纳指期货跌0.03%，标普500指数期货跌0.13%。$诺和诺德$涨超3%，Wegovy获FDA批准用于治疗肝病。$Tonix Pharmaceuticals$涨超11%，其纤维肌痛新药获FDA批准。部分中概股走高，$迅雷$涨超15%，$爱奇艺$涨超9%，$金山云$涨近6%，$理想汽车$、$小鹏汽车$、$蔚来$涨超1%。加密概念股下挫，$Upexi$、$BitMine$跌超4%，$SharpLink$跌超3%，$Bit Digital$、$Strategy$、$MARA Holdings$跌超2%。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","NIO","XPEV","TNXP","NVO","BK4147","BK4116","BK4139","MSTR.AU","BTBT","SBET","BK4099","XNET","SHCO","NVO.AU","BK4531","BK4526","LU1093756168.USD","BMNR","MARA","BK4023","BK4532","IQ","BK4583","LI","BK4585","KC","UPXI","MSTR"],"gpt_icon":0},{"id":"2560977506","title":"美股异动丨Tonix盘前涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560977506","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560977506?lang=zh_cn&edition=full","pubTime":"2025-08-18 16:12","pubTimestamp":1755504761,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ad16bf258724617c5157afa8ededbfd2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","TNXP","BK4583"],"gpt_icon":0},{"id":"1103633394","title":"异动解读 | Tonix制药夜盘大涨18.79%，FDA批准其纤维肌痛新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1103633394","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103633394?lang=zh_cn&edition=full","pubTime":"2025-08-18 08:26","pubTimestamp":1755476783,"startTime":"0","endTime":"0","summary":"周日夜盘交易中，Tonix Pharmaceuticals Holding Co股价大幅上涨18.79%，引发市场广泛关注。这一显著涨幅主要源于该公司重大利好消息的公布。据悉，美国食品和药物管理局已批准Tonix制药用于治疗纤维肌痛相关疼痛的新药。这款名为Tonmya的非阿片类药物是15年来首个获批用于纤维肌痛治疗的新药，为患者提供了新的治疗选择。考虑到目前纤维肌痛治疗市场存在巨大缺口，Tonix制药此次获批无疑为公司开辟了广阔的市场空间，这也解释了投资者对公司股票的热烈追捧。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TNXP"],"gpt_icon":0},{"id":"1102966918","title":"美国FDA批准Tonix Pharmaceuticals用于治疗慢性病相关疼痛的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1102966918","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102966918?lang=zh_cn&edition=full","pubTime":"2025-08-18 08:22","pubTimestamp":1755476576,"startTime":"0","endTime":"0","summary":"$Tonix Pharmaceuticals Holding Co$ 上周五表示，美国食品和药物管理局已批准其用于治疗一种名为纤维肌痛的慢性病相关疼痛的药物。此次获批为该药成为15年多来纤维肌痛患者的首个新治疗选择铺平了道路。这种非阿片类药物将以Tonmya为品牌名销售，是一种专为睡前治疗设计的药片，旨在改善睡眠质量并减轻这种慢性病相关的疼痛。Tonix向卫生监管机构提交的申请基于两项后期研究。扎克斯小盘股研究公司分析师戴维·鲍茨表示，这对Tonix来说是一个巨大的机会。","market":"us","thumbnail":"https://community-static.tradeup.com/news/12d14980c1b27536197b89096219ad7a","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/12d14980c1b27536197b89096219ad7a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美国FDA批准Tonix Pharmaceuticals用于治疗慢性病相关疼痛的药物","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP"],"gpt_icon":1},{"id":"1107491031","title":"异动解读 | 托尼克斯制药盘前大涨7.28%，尽管季度业绩不及预期，分析师仍看好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1107491031","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107491031?lang=zh_cn&edition=full","pubTime":"2025-08-15 16:04","pubTimestamp":1755245087,"startTime":"0","endTime":"0","summary":"美国生物制药公司托尼克斯制药控股公司周五盘前大涨7.28%，引发市场广泛关注。这一显著涨幅出现在公司发布第二季度财报后，尽管财报显示业绩不及预期。根据最新发布的财报，托尼克斯制药第二季度调整后每股亏损3.86美元，高于分析师预期的3.21美元亏损。值得注意的是，尽管季度业绩欠佳，托尼克斯制药的股价表现依然强劲。分析师给予托尼克斯制药12个月目标价中位数为65.00美元，较前一交易日收盘价高出约5.3%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TNXP"],"gpt_icon":1},{"id":"1176210092","title":"异动解读 | 托尼克斯制药盘前大涨7.28%，尽管季度业绩不及预期，分析师仍看好前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1176210092","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176210092?lang=zh_cn&edition=full","pubTime":"2025-08-15 16:04","pubTimestamp":1755245081,"startTime":"0","endTime":"0","summary":"美国生物制药公司托尼克斯制药控股公司周五盘前大涨7.28%，引发市场广泛关注。这一显著涨幅出现在公司发布第二季度财报后，尽管业绩不及预期，但投资者似乎对公司的长期发展前景保持乐观。尽管季度业绩表现不佳，托尼克斯制药的股价本季度已累计上涨71.1%，今年迄今为止更是上涨了86.7%，显示出投资者对公司的持续信心。值得注意的是，尽管季度业绩不及预期，分析师仍对托尼克斯制药保持积极态度。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TNXP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tonixpharma.com;www.tonix.com","stockEarnings":[{"period":"1week","weight":-0.0558},{"period":"1month","weight":0.0497},{"period":"3month","weight":-0.073},{"period":"6month","weight":-0.7361},{"period":"1year","weight":0.3115},{"period":"ytd","weight":0.0403}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tonix Pharmaceuticals Holding Corp.2007年11月16日在内华达州成立。该公司是一家临床阶段的生物制药公司，专注于开发治疗和预防人类疾病和减轻痛苦的疗法和疫苗。该公司拥有大量正在开发的产品，这些产品是通过内部发现、许可、收购以及与学术机构和合同研究组织的合作来策划的。公司继续在合成生物学、精准医学、蛋白质工程、药物化学、分子生物学、药物基因组学和临床规模制造方面建设能力。该公司正在开发的疗法包括小分子和生物制剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.692308,"avgChangeRate":0.190798},{"month":2,"riseRate":0.153846,"avgChangeRate":-0.151515},{"month":3,"riseRate":0.416667,"avgChangeRate":0.038421},{"month":4,"riseRate":0.25,"avgChangeRate":-0.073521},{"month":5,"riseRate":0.416667,"avgChangeRate":0.017213},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.071625},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.11658},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.140207},{"month":9,"riseRate":0.153846,"avgChangeRate":-0.25769},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.06224},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.060378},{"month":12,"riseRate":0.538462,"avgChangeRate":0.052728}],"exchange":"NASDAQ","name":"Tonix Pharmaceuticals Holding Co","nameEN":"Tonix Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tonix Pharmaceuticals Holding Co(TNXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tonix Pharmaceuticals Holding Co,TNXP,Tonix Pharmaceuticals Holding Co股票,Tonix Pharmaceuticals Holding Co股票老虎,Tonix Pharmaceuticals Holding Co股票老虎国际,Tonix Pharmaceuticals Holding Co行情,Tonix Pharmaceuticals Holding Co股票行情,Tonix Pharmaceuticals Holding Co股价,Tonix Pharmaceuticals Holding Co股市,Tonix Pharmaceuticals Holding Co股票价格,Tonix Pharmaceuticals Holding Co股票交易,Tonix Pharmaceuticals Holding Co股票购买,Tonix Pharmaceuticals Holding Co股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tonix Pharmaceuticals Holding Co(TNXP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tonix Pharmaceuticals Holding Co(TNXP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}